Lilly Is Suing Retatrutide Sellers: What the Company Alleges, and What Is Not Yet Known
Published: November 4, 2026 · 4 min read · By Grey Peptides News Desk · ✓ Sourced
Eli Lilly, which makes retatrutide, has started suing US businesses it says sell the drug outside its clinical trials. On August 12, 2026 the company said it had filed six federal lawsuits in California and Texas, and news outlets reported more suits on October 8. Retatrutide is not approved anywhere. The lawsuits are Lilly's side of the story: they are allegations, and no court has decided them. Poison-center figures for retatrutide have also been circulating, but we could not trace them to anything America's Poison Centers itself has published, so we do not repeat them.
What Lilly says it filed
In its August 12 release, Lilly said it had filed six new lawsuits against businesses in the United States that sell retatrutide products. One was filed in the Northern District of California, two in the Western District of Texas, one in the Eastern District of Texas and two in the Southern District of Texas. The companies named include online peptide sellers, a medical spa and a pharmacy. We do not name them: this site never names a seller, including one that has been sued.
The federal docket for the Eastern District of Texas case shows Lilly's complaint, a request for a jury trial and a summons, all dated August 12, 2026. Complaints in federal court are kept behind the courts' paid records system, and we could not read them, so this post does not describe the specific legal claims. Law-firm summaries of those claims exist, but they are not the filings themselves.
The October suits
On October 8, news outlets reported that Lilly had sued more businesses over retatrutide. We could not find a Lilly statement about those suits or read the complaints, and the reports do not agree on how many were filed. We therefore give no number for them. If Lilly or the court records confirm the October filings, we will update this post.
Allegations, not findings
A complaint is one side's account of a dispute. Each defendant can answer it, contest it, settle or ask the court to dismiss it. The docket we could read lists only the opening filings, with no ruling. Until a court decides a case or a defendant admits the claims, what Lilly says about any of these businesses remains an allegation.
What else Lilly reports
Lilly says it has referred more than 200 people and businesses to FDA, the Justice Department, state attorneys general, police and professional licensing boards. It also says it has reported more than 14,000 websites, adverts, social media posts and product listings in more than 100 countries to the platforms that host them. These figures are the company's own and cannot be checked from outside.
The release repeats the basic facts. Retatrutide is an investigational drug in phase 3 trials, no regulator anywhere has approved it, and so it cannot lawfully be sold to consumers. Lilly's chief medical officer said that what is sold on the black market "is not a medicine." Lilly is asking platforms, payment companies and shipping firms to stop serving these sellers, and it asks regulators to treat the sales as an urgent problem.
The poison-center figures
In October, retatrutide exposure counts attributed to America's Poison Centers appeared in news reports. We looked for them in the organisation's own publications: its GLP-1 hazard page, its news page and its public trends page. None gives a figure for retatrutide. Its public figures cover GLP-1 drugs as a group. Because we could not trace the retatrutide numbers to their source, we leave them out. That does not mean the numbers are wrong. It means we cannot show you where they come from.
What this means for a buyer
None of this changes retatrutide's status. Outside Lilly's trials and its expanded-access programme, there is no lawful supply. A vial sold online or by a clinic did not come from Lilly, and nothing on its label shows what is actually inside. Our guide to retatrutide testing sets out what a lab report on one of these products can show, and what it cannot.
Related on Grey Peptides
The trials, the doses studied and its regulatory status. Retatrutide testing and its limits
What lab reports on these products show, and what they miss. Retatrutide filing planned for 2027
Lilly's submission plan and its expanded-access programme. What 'research use only' means
Why the label does not make a product legal to inject.
Lilly's release was read in full on November 4, 2026; the lawsuit counts, courts and enforcement figures are the company's own. The filing date was checked on the public federal docket for one of the six cases. America's Poison Centers' public pages were read the same day and give no retatrutide figure. We name no defendant, by policy.